Integrated Filing — IndAS



General information about company

Scrip Code 540975
NSE Symbol ASTERDM
MSEI Symbol NOTLISTED
ISIN INE914M01019
Name of company Aster DM Healthcare Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 30-04-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 25-04-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 30-04-2026   10:30:00
End date and time of board meeting 30-04-2026   15:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,18,238.00 4,64,322.00
Other income 3,620.00 12,560.00
Total income 1,21,858.00 4,76,882.00
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 25,897.00 1,04,761.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 419.00 118.00
(d) Employee benefit expense 21,999.00 84,809.00
(e) Finance costs 2,999.00 12,298.00
(f) Depreciation, depletion and amortisation expense 6,724.00 26,425.00
(f) Other Expenses
1 Professional fees to consultant doctors 26,466.00 1,03,187.00
2 Laboratory outsourcing charges 535.00 2,752.00
3 Other expenses 19,664.00 78,592.00
4 0 0.00 0.00
5 0 0.00 0.00
6 0 0.00 0.00
7 0 0.00 0.00
8 0 0.00 0.00
9 0 0.00 0.00
10 0 0.00 0.00
Total other expenses 46,665.00 1,84,531.00
Total expenses 1,04,703.00 4,12,942.00
3 Total profit before exceptional items and tax 17,155.00 63,940.00
4 Exceptional items 33.00 (3,271.00)
5 Total profit before tax 17,188.00 60,669.00
6 Tax expense
7 Current tax 3,637.00 18,603.00
8 Deferred tax (2,660.00) (4,344.00)
9 Total tax expenses 977.00 14,259.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 16,211.00 46,410.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (853.00) (3,700.00)
16 Total profit (loss) for period 15,358.00 42,710.00
17 Other comprehensive income net of taxes 260.00 36.00
18 Total Comprehensive Income for the period 15,618.00 42,746.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 14,017.00 38,814.00
Total profit or loss, attributable to non-controlling interests 1,341.00 3,896.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 14,256.00 38,852.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 1,362.00 3,894.00
21 Details of equity share capital
Paid-up equity share capital 51,813.00 51,813.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 3,70,917.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.72 7.53
Diluted earnings (loss) per share from continuing operations 2.71 7.52
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.72 7.53
Diluted earnings (loss) per share from continuing and discontinued operations 2.71 7.52
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 2,61,874.00
Capital work-in-progress 41,259.00
Investment property 0.00
Goodwill 26,412.00
Other intangible assets 1,925.00
Intangible assets under development 702.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 19,390.00
Non-current financial assets
Non-current investments 97,125.00
Trade receivables, non-current 0.00
Loans, non-current 125.00
Other non-current financial assets
1 Other non-current financial assets 13,627.00
2 0 0.00
3 0 0.00
4 0 0.00
5 0 0.00
6 0 0.00
Total of other non-current financial assets 13,627.00
Total non-current financial assets 1,10,877.00
Deferred tax assets (net) 3,620.00
Other non-current assets
1 Other non-current assets 9,024.00
2 Income tax assets 7,380.00
3 Right-of-use assets 1,33,954.00
4 0 0.00
5 0 0.00
Total of other non-current assets 1,50,358.00
Total non-current assets 6,16,417.00
2 Current assets
Inventories 9,116.00
Current financial asset
Current investments 141.00
Trade receivables, current 30,723.00
Cash and cash equivalents 22,807.00
Bank balance other than cash and cash equivalents 1,09,729.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 15,860.00
Total current financial assets 1,79,260.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 6,403.00
2 0 0.00
3 0 0.00
4 0 0.00
5 0 0.00
Total of other current assets 6,403.00
Total current assets 1,94,779.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 8,11,196.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 51,813.00
Other equity 4,05,773.00
Total equity attributable to owners of parent 4,57,586.00
Non controlling interest 25,784.00
Total equity 4,83,370.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 55,844.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 1,48,883.00
2 Other non current financial liabilities 378.00
3 0 0.00
4 0 0.00
5 0 0.00
Total of other non-current financial liabilities 1,49,261.00
Total non-current financial liabilities 2,05,105.00
Provisions, non-current 5,343.00
Deferred tax liabilities (net) 13,282.00
Deferred government grants, Non-current 6,180.00
Other non-current liabilities
1 0 0.00
2 0 0.00
3 0 0.00
4 0 0.00
5 0 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 2,29,910.00
Current liabilities
Current financial liabilities
Borrowings, current 14,274.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 4,442.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 43,709.00
Total Trade payable 48,151.00
Other current financial liabilities
1 Lease liabilities 2,965.00
2 Other current financial liabilities 8,996.00
3 0 0.00
4 0 0.00
5 0 0.00
Total of other current financial liabilities 11,961.00
Total current financial liabilities 74,386.00
Other current liabilities 21,386.00
1 Other current liabilities 21,386.00
2 0 0.00
3 0 0.00
4 0 0.00
5 0 0.00
Total of other current liabilities 21,386.00
Provisions, current 1,206.00
Current tax liabilities (Net) 1.00
Deferred government grants, Current 937.00
Total current liabilities 97,916.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,27,826.00
Total equity and liabilites 8,11,196.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Hospitals & Clinics 1,15,256.00 4,50,639.00
2 Labs 3,851.00 15,350.00
3 Wholesale Pharmacies 1,977.00 10,832.00
4 Others 0.00517 1,479.00
5 0 0.00 0.00
6 0 0.00 0.00
7 0 0.00 0.00
8 0 0.00 0.00
9 0 0.00 0.00
10 0 0.00 0.00
11 0 0.00 0.00
12 0 0.00 0.00
13 0 0.00 0.00
14 0 0.00 0.00
15 0 0.00 0.00
Total Segment Revenue 1,21,601.00 4,78,300.00
Less: Inter segment revenue 3,363.00 13,978.00
Revenue from operations 1,18,238.00 4,64,322.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Hospitals & Clinics 20,681.00 78,042.00
2 Labs 398.00 1,484.00
3 Wholesale Pharmacies (36.00) 79.00
4 Others (109.00) (1,700.00)
5 0 0.00 0.00
6 0 0.00 0.00
7 0 0.00 0.00
8 0 0.00 0.00
9 0 0.00 0.00
10 0 0.00 0.00
11 0 0.00 0.00
12 0 0.00 0.00
13 0 0.00 0.00
14 0 0.00 0.00
15 0 0.00 0.00
Total Profit before tax 20,934.00 77,905.00
i. Finance cost 2,999.00 12,298.00
ii. Other Unallocable Expenditure net off Unallocable income 1,600.00 8,638.00
Profit before tax 16,335.00 56,969.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Hospitals & Clinics 6,71,199.00 6,71,199.00
2 Labs 8,334.00 8,334.00
3 Wholesale Pharmacies 5,534.00 5,534.00
4 Others 2,662.00 2,662.00
5 0 0.00 0.00
6 0 0.00 0.00
7 0 0.00 0.00
8 0 0.00 0.00
9 0 0.00 0.00
10 0 0.00 0.00
11 0 0.00 0.00
12 0 0.00 0.00
13 0 0.00 0.00
14 0 0.00 0.00
15 0 0.00 0.00
Total Segment Asset 6,87,729.00 6,87,729.00
Un-allocable Assets 1,23,467.00 1,23,467.00
Net Segment Asset 8,11,196.00 8,11,196.00
4 Segment Liabilities
Segment Liabilities
1 Hospitals & Clinics 2,93,745.00 2,93,745.00
2 Labs 5,951.00 5,951.00
3 Wholesale Pharmacies 875.00 875.00
4 Others 0.00 0.00
5 0 0.00 0.00
6 0 0.00 0.00
7 0 0.00 0.00
8 0 0.00 0.00
9 0 0.00 0.00
10 0 0.00 0.00
11 0 0.00 0.00
12 0 0.00 0.00
13 0 0.00 0.00
14 0 0.00 0.00
15 0 0.00 0.00
Total Segment Liabilities 3,00,571.00 3,00,571.00
Un-allocable Liabilities 27,255.00 27,255.00
Net Segment Liabilities 3,27,826.00 3,27,826.00
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of net defined benefit liability 272.00 (22.00)
Total Amount of items that will not be reclassified to profit and loss 272.00 (22.00)
2 Income tax relating to items that will not be reclassified to profit or loss 65.00 (5.00)
3 Amount of items that will be reclassified to profit and loss
1 Exchange difference in translating financial statements of foreign operations 73.00 73.00
Total Amount of items that will be reclassified to profit and loss 73.00 73.00
4 Income tax relating to items that will be reclassified to profit or loss 20.00 20.00
5 Total Other comprehensive income 260.00 36.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 60,669.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 12,298.00
Adjustments for decrease (increase) in inventories 119.00
Adjustments for decrease (increase) in trade receivables, current (6,174.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (9,602.00)
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 26,425.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 6,148.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 10,327.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (192.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 187.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 2,063.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 20,945.00
Net cash flows from (used in) operations 81,614.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 16,022.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 65,592.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 307.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 70.00
Purchase of property, plant and equipment 46,908.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 844.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 6,776.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 12,392.00
Net cash flows from (used in) investing activities (28,821.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 8,194.00
Proceeds from issuing shares 250.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 16,497.00
Repayments of borrowings 15,039.00
Payments of lease liabilities 13,117.00
Dividends paid 5,513.00
Interest paid 5,318.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (30,434.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 6,337.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 11.00
Net increase (decrease) in cash and cash equivalents 6,348.00
Cash and cash equivalents cash flow statement at beginning of period 16,459.00
Cash and cash equivalents cash flow statement at end of period 22,807.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/S Deloitte Haskins & Sells Yes 30-04-2028